硫酸镁联合拉贝洛尔治疗妊娠期高血压的临床疗效及其对母婴结局的影响
|
摘要
目的分析硫酸镁联合拉贝洛尔治疗妊娠期高血压的临床疗效及其对母婴结局的影响。方法选取2016年8月至2018年10月于西北妇女儿童医院就诊的妊娠期高血压患者180例,对照组与观察组各90例。对照组患者行硫酸镁降压治疗,观察组患者行硫酸镁与拉贝洛尔联合治疗。对比两组患者治疗前后血压、血液流变学以及血浆因子浓度变化,记录两组患者母婴结局。结果①治疗后,观察组全血还原黏度、全血黏度、血浆MDA水平均低于对照组(P<0.05)),NO、SOD水平明显增高(P<0.05);②观察组患者产后大出血发生率低于对照组(P<0.05),新生儿宫内窘迫与早产发生率明显低于对照组(P<0.05)。结论硫酸镁联合拉贝洛尔治疗妊娠期高血压具有显著的临床疗效,通过血管内皮细胞功能的改善以及氧自由基的降低,使得妊娠期高血压患者的血压及尿蛋白水平得到明显的改善,母婴结局良好且安全性高。
Objective To analyze the clinical efficacy of magnesium sulfate combined with labetalol in the treatment of hypertensive disorder complicating pregnancy and its effect on maternal and infant outcomes.Methods 180 patients with gestational hypertension who were admitted to the Northwest Women and Children Hospital from August 2016 to October 2018 were enrolled,and 90 patients in the control group and the observation group. The patients in the control group were treated with magnesium sulfate and the patients in the observation group were treated with magnesium sulfate and labetalol. Blood pressure,hemorheology and plasma factor concentrations were compared before and after treatment. The maternal and infant outcomes of the two groups were recorded. Results ①After treatment,the whole blood reduction viscosity,whole blood viscosity,plasma MDA level of the observation group were lower than the control group(P<0.05),and the levels of NO and SOD were significantly increased(P<0.05);②Patients in the observation group The incidence of postpartum hemorrhage was lower than that of the control group(P<0.05),and the incidence of intrauterine distress and preterm birth was significantly lower than that of the control group(P<0.05). Conclusion Magnesium sulfate combined with labetalol has significant clinical efficacy in the treatment of hypertensive disorder complicating pregnancy. Through the improvement of vascular endothelial cell function and the decrease of oxygen free radicals,the blood pressure and urine protein levels of hypertensive patients with pregnancy are significantly improved. The baby has a good ending and is safe.
Objective To analyze the clinical efficacy of magnesium sulfate combined with labetalol in the treatment of hypertensive disorder complicating pregnancy and its effect on maternal and infant outcomes.Methods 180 patients with gestational hypertension who were admitted to the Northwest Women and Children Hospital from August 2016 to October 2018 were enrolled,and 90 patients in the control group and the observation group. The patients in the control group were treated with magnesium sulfate and the patients in the observation group were treated with magnesium sulfate and labetalol. Blood pressure,hemorheology and plasma factor concentrations were compared before and after treatment. The maternal and infant outcomes of the two groups were recorded. Results ①After treatment,the whole blood reduction viscosity,whole blood viscosity,plasma MDA level of the observation group were lower than the control group(P<0.05),and the levels of NO and SOD were significantly increased(P<0.05);②Patients in the observation group The incidence of postpartum hemorrhage was lower than that of the control group(P<0.05),and the incidence of intrauterine distress and preterm birth was significantly lower than that of the control group(P<0.05). Conclusion Magnesium sulfate combined with labetalol has significant clinical efficacy in the treatment of hypertensive disorder complicating pregnancy. Through the improvement of vascular endothelial cell function and the decrease of oxygen free radicals,the blood pressure and urine protein levels of hypertensive patients with pregnancy are significantly improved. The baby has a good ending and is safe.
引文
[1]张彩玩,黄素静,于春玲.硫酸镁注射液联合拉贝洛尔注射液和尼莫地平片治疗妊娠高血压的临床研究[J].中国临床药理学杂志,2018,34(8):926-929.
[2]杜鸿琴,钟镇强,郭奕强.硫酸镁联合拉贝洛尔治疗妊娠期高血压疗效及母婴结局影响分析[J].齐齐哈尔医学院学报,2017,38(11):1313-1314.
[3]谢桂英,马玉燕.拉贝洛尔对中重度妊娠期高血压疾病患者心肾功能及妊娠结局的影响及机制[J].山东医药,2017,57(21):80-82.
[4]谢幸,苟文丽等.妇产科学[M].8版.北京:人民卫生出版社,2014.
[5]周静,王毅,朱彦菲.拉贝洛尔注射液联合硝苯地平控释片治疗妊娠高血压的临床研究[J].中国临床药理学杂志,2018(11):1315-0317..
[6]刘羽.拉贝洛尔联合硫酸镁治疗妊娠期高血压疾病患者的疗效及对母婴结局的影响[J].中国妇幼保健,2017,32(23):5838-5840.
[7]徐嵘.硫酸镁联合拉贝洛尔治疗对重症妊娠期高血压患者血压、血清同型半胱氨酸及C-反应蛋白水平的影响[J].中国妇幼保健,2018(5):1028-1030.
[8]陈娜,江继芬,宋学敏,等.拉贝洛尔联合硫酸镁治疗对妊娠高血压产妇血清尿酸及母婴结局的影响[J].解放军预防医学杂志,2018(a01):35-37.
[9]赵欣媛,王月玲,郑雪绒.拉贝洛尔治疗重度妊娠期高血压临床效果分析[J].解放军预防医学杂志,2016(s1):44-45.
[10]王亚军.拉贝洛尔联合硫酸镁治疗妊娠高血压疾病的临床效果观察及不良反应评价[J].河北医科大学学报,2016,37(10):1211-1214.
[11]屈秋慧,邵美丽,吴胜军,等.尼莫地平与盐酸拉贝洛尔联合丹参注射液对妊娠期高血压患者血清前列腺素E2、Apelin水平及母婴结局的影响[J].实用心脑肺血管病杂志,2018,26(4):133-135.
[12]王晓临,肖建平.硫酸镁联合拉贝洛尔治疗早发型重度子痫前期效果观察[J].山东医药,2016,56(44):63-64.
[13]常春玲,孙鸿,林林,等.早发型重度子痫前期患者应用拉贝洛尔治疗对母婴结局以及PT、Fg等的影响[J].检验医学与临床,2017,14(1):94-97.
[14]代培培.拉贝洛尔联合硫酸镁治疗重症妊娠高血压的疗效和分娩结局研究[J].山西医药杂志,2018(5):557-559.
[2]杜鸿琴,钟镇强,郭奕强.硫酸镁联合拉贝洛尔治疗妊娠期高血压疗效及母婴结局影响分析[J].齐齐哈尔医学院学报,2017,38(11):1313-1314.
[3]谢桂英,马玉燕.拉贝洛尔对中重度妊娠期高血压疾病患者心肾功能及妊娠结局的影响及机制[J].山东医药,2017,57(21):80-82.
[4]谢幸,苟文丽等.妇产科学[M].8版.北京:人民卫生出版社,2014.
[5]周静,王毅,朱彦菲.拉贝洛尔注射液联合硝苯地平控释片治疗妊娠高血压的临床研究[J].中国临床药理学杂志,2018(11):1315-0317..
[6]刘羽.拉贝洛尔联合硫酸镁治疗妊娠期高血压疾病患者的疗效及对母婴结局的影响[J].中国妇幼保健,2017,32(23):5838-5840.
[7]徐嵘.硫酸镁联合拉贝洛尔治疗对重症妊娠期高血压患者血压、血清同型半胱氨酸及C-反应蛋白水平的影响[J].中国妇幼保健,2018(5):1028-1030.
[8]陈娜,江继芬,宋学敏,等.拉贝洛尔联合硫酸镁治疗对妊娠高血压产妇血清尿酸及母婴结局的影响[J].解放军预防医学杂志,2018(a01):35-37.
[9]赵欣媛,王月玲,郑雪绒.拉贝洛尔治疗重度妊娠期高血压临床效果分析[J].解放军预防医学杂志,2016(s1):44-45.
[10]王亚军.拉贝洛尔联合硫酸镁治疗妊娠高血压疾病的临床效果观察及不良反应评价[J].河北医科大学学报,2016,37(10):1211-1214.
[11]屈秋慧,邵美丽,吴胜军,等.尼莫地平与盐酸拉贝洛尔联合丹参注射液对妊娠期高血压患者血清前列腺素E2、Apelin水平及母婴结局的影响[J].实用心脑肺血管病杂志,2018,26(4):133-135.
[12]王晓临,肖建平.硫酸镁联合拉贝洛尔治疗早发型重度子痫前期效果观察[J].山东医药,2016,56(44):63-64.
[13]常春玲,孙鸿,林林,等.早发型重度子痫前期患者应用拉贝洛尔治疗对母婴结局以及PT、Fg等的影响[J].检验医学与临床,2017,14(1):94-97.
[14]代培培.拉贝洛尔联合硫酸镁治疗重症妊娠高血压的疗效和分娩结局研究[J].山西医药杂志,2018(5):557-559.